$2.80
1.64% today
Nasdaq, Sep 23, 06:19 pm CET

Maravai LifeSciences Stock price

$2.75
+0.30 12.24% 1M
+0.51 22.77% 6M
-2.70 49.54% YTD
-5.55 66.87% 1Y
-21.80 88.80% 3Y
-27.10 90.79% 5Y
-27.10 90.79% 10Y
-27.10 90.79% 20Y
Nasdaq, Closing price Mon, Sep 22 2025
+0.05 1.85%

Key metrics

Basic
Market capitalization
$702.2m
Enterprise Value
$757.7m
Net debt
$55.5m
Cash
$269.9m
Shares outstanding
255.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.3 | 3.6
EV/Sales
3.5 | 3.9
EV/FCF
negative
P/B
2.6
Financial Health
Equity Ratio
32.3%
Return on Equity
-44.5%
ROCE
-13.7%
ROIC
-18.6%
Debt/Equity
1.2
Financials (TTM | estimate)
Revenue
$215.9m | $195.6m
EBITDA
$-112.5m | $-28.2m
EBIT
$-113.6m | $-80.6m
Net Income
$-194.7m | $-81.6m
Free Cash Flow
$-45.2m
Growth (TTM | estimate)
Revenue
-22.5% | -24.6%
EBITDA
-70,381.3% | 58.6%
EBIT
-148.8% | -14.0%
Net Income
-47.4% | 43.7%
Free Cash Flow
-166.3%
Margin (TTM | estimate)
Gross
29.1%
EBITDA
-52.1% | -14.4%
EBIT
-52.7%
Net
-90.2% | -41.7%
Free Cash Flow
-20.9%
More
EPS
$-1.4
FCF per Share
$-0.2
Short interest
11.4%
Employees
580
Rev per Employee
$450.0k
Show more

Is Maravai LifeSciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Maravai LifeSciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Maravai LifeSciences forecast:

11x Buy
61%
7x Hold
39%

Analyst Opinions

18 Analysts have issued a Maravai LifeSciences forecast:

Buy
61%
Hold
39%

Financial data from Maravai LifeSciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
216 216
23% 23%
100%
- Direct Costs 153 153
3% 3%
71%
63 63
52% 52%
29%
- Selling and Administrative Expenses 157 157
1% 1%
73%
- Research and Development Expense 19 19
0% 0%
9%
-112 -112
70,381% 70,381%
-52%
- Depreciation and Amortization 1.20 1.20
97% 97%
1%
EBIT (Operating Income) EBIT -114 -114
149% 149%
-53%
Net Profit -195 -195
47% 47%
-90%

In millions USD.

Don't miss a Thing! We will send you all news about Maravai LifeSciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Maravai LifeSciences Stock News

Neutral
GlobeNewsWire
14 days ago
Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Maravai (MRVI) To Contact Him Directly To Discuss Their Options If you purchased or acquired common stock in Maravai LifeSciences between August 7, 2024 and February 24, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner  Brandon Walker or Marion Passmore...
Neutral
Seeking Alpha
about one month ago
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q2 2025 Earnings Conference Call August 11, 2025 5:00 PM ET Company Participants Bernd Brust - CEO & Director Debra Hart - Senior Director of Investor Relations Rajesh J. Asarpota - EVP & Chief Financial Officer Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Catherine Walden Ramsey Schulte - Robe...
Neutral
GlobeNewsWire
about one month ago
Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings
More Maravai LifeSciences News

Company Profile

Maravai Lifesciences Holdings, Inc. operates as an investment holding company. It develops biopharmaceuticals. The company is headquartered in San Diego, CA.

Head office United States
CEO William Martin
Employees 580
Founded 2014
Website www.maravai.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today